{"id":16243,"date":"2025-07-15T13:30:18","date_gmt":"2025-07-15T13:30:18","guid":{"rendered":"https:\/\/genekor.com\/?p=16243"},"modified":"2025-08-07T06:48:42","modified_gmt":"2025-08-07T06:48:42","slug":"pik3ca-adjuvantni-lecba-kolorektalni-karcinom","status":"publish","type":"post","link":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/","title":{"rendered":"AKTUALIZOVAN\u00c9 DOPORU\u010cEN\u00c9 POSTUPY NCCN PRO \u010cASN\u00c1 STADIA KOLOREKT\u00c1LN\u00cdHO KARCINOMU: V\u00ddZNAM BIOMARKER\u016e PIK3CA, POLE A MSI V \u0158\u00cdZEN\u00cd ADJUVANTN\u00cd L\u00c9\u010cBY"},"content":{"rendered":"\n<p>Nep\u0159etr\u017eit\u00fd v\u00fdvoj v oblasti molekul\u00e1rn\u00ed onkologie z\u00e1sadn\u00edm zp\u016fsobem m\u011bn\u00ed terapeutick\u00fd p\u0159\u00edstup k l\u00e9\u010db\u011b kolorekt\u00e1ln\u00edho karcinomu. V\u00fdsledky studie <a href=\"https:\/\/mcusercontent.com\/84034efa59a7e43f306956007\/files\/94270538-3fd9-8b84-07d7-ce4aa8a388fe\/lindberg_et_al_2025_low_dose_aspirin_to_reduce_recurrence_rate_in_colorectal_cancer_patients_with_pi3k_pathway.pdf\">ALASCCA, prezentovan\u00e9 na kongresu ASCO GI 2025<\/a>, spolu s aktualizovan\u00fdmi doporu\u010den\u00edmi <strong>NCCN pro rok 2025<\/strong>, zd\u016fraz\u0148uj\u00ed v\u00fdznam specifick\u00fdch molekul\u00e1rn\u00edch marker\u016f \u2013 mutac\u00ed <strong>gen\u016f PIK3CA, POLE a statusu mikrosatelitov\u00e9 nestability (MSI)<\/strong> \u2013 pro personalizaci adjuvantn\u00ed terapie u pacient\u016f s karcinomem tlust\u00e9ho st\u0159eva ve stadi\u00edch II\u2013III, zejm\u00e9na u t\u011bch, kte\u0159\u00ed vykazuj\u00ed aberace <strong>v dr\u00e1ze PI3K.<\/strong><\/p>\n\n\n\n<p>Mutace genu <strong>PIK3CA<\/strong> byly ve studii zaznamen\u00e1ny u 37% pacient\u016f, p\u0159i\u010dem\u017e p\u0159edstavuj\u00ed nej\u010dast\u011bj\u0161\u00ed molekul\u00e1rn\u00ed alteraci v dan\u00e9 kohort\u011b. Na z\u00e1klad\u011b t\u011bchto dat bylo vy\u0161et\u0159en\u00ed <strong>PIK3CA<\/strong> nov\u011b za\u0159azeno mezi doporu\u010den\u00e1 vy\u0161et\u0159en\u00ed v r\u00e1mci doporu\u010den\u00fdch postup\u016f <strong>NCCN<\/strong>, s mo\u017enost\u00ed zv\u00e1\u017een\u00ed pod\u00e1v\u00e1n\u00ed kyseliny acetylsalicylov\u00e9 (aspirinu) u t\u00e9to specifick\u00e9 molekul\u00e1rn\u011b definovan\u00e9 podskupiny pacient\u016f.<\/p>\n\n\n\n<p>Aktualizovan\u00e1 doporu\u010den\u00ed rovn\u011b\u017e vyzdvihuj\u00ed prognostick\u00fd v\u00fdznam mutac\u00ed POLE, p\u0159\u00edtomnosti deficitu opravn\u00fdch mechanism\u016f DNA (dMMR) a vysok\u00e9 mikrosatelitov\u00e9 nestability (MSI-H). Tyto biomarkery jsou spojeny s p\u0159\u00edzniv\u011bj\u0161\u00ed progn\u00f3zou a mohou p\u0159isp\u011bt ke sn\u00ed\u017een\u00ed rizika zbyte\u010dn\u00e9 expozice adjuvantn\u00ed terapii. Mutace v genu <strong>POLE se vyskytuj\u00ed p\u0159ibli\u017en\u011b u 2.09%<\/strong> <strong>pacient\u016f ve stadiu II a u 0.66% ve stadiu III,<\/strong> p\u0159i\u010dem\u017e se nevyskytuj\u00ed sou\u010dasn\u011b s deficitem opravn\u00fdch mechanism\u016f DNA (jsou navz\u00e1jem exkluzivn\u00ed).<\/p>\n\n\n\n<p>A\u010dkoli sou\u010dasn\u00e1 doporu\u010den\u00ed NCCN zat\u00edm nepodporuj\u00ed rutinn\u00ed vyu\u017e\u00edv\u00e1n\u00ed rozs\u00e1hl\u00fdch multigenov\u00fdch panel\u016f pro rozhodov\u00e1n\u00ed o indikaci adjuvantn\u00ed l\u00e9\u010dby v \u010dasn\u00fdch stadi\u00edch kolorekt\u00e1ln\u00edho karcinomu, nov\u00e9 d\u016fkazy nazna\u010duj\u00ed, \u017ee vybran\u00e9 molekul\u00e1rn\u00ed biomarkery mohou v\u00e9st k personalizaci terapie.<\/p>\n\n\n\n<p>Molekul\u00e1rn\u00ed panel<strong> Com.pl.i.t DX Colon<\/strong>, ji\u017e zaveden\u00fd u pacient\u016f s metastazuj\u00edc\u00edm kolorekt\u00e1ln\u00edm karcinomem (mCRC), zahrnuje anal\u00fdzu gen\u016f <strong>PIK3CA, POLE a statusu MSI<\/strong>, \u010d\u00edm\u017e poskytuje ucelen\u00fd molekul\u00e1rn\u011b-genetick\u00fd profil, kter\u00fd reflektuje sou\u010dasn\u00e9 poznatky a doporu\u010den\u00ed.<\/p>\n\n\n\n<p>S ohledem na aktu\u00e1ln\u00ed data m\u016f\u017ee b\u00fdt test <strong>Com.pl.i.t DX Colon cenn\u00fdm n\u00e1strojem pro rozhodovac\u00ed proces p\u0159i volb\u011b adjuvantn\u00ed l\u00e9\u010dby i u \u010dasn\u00fdch stadi\u00ed kolorekt\u00e1ln\u00edho karcinomu (stadia II\u2013III)<\/strong>, a to jak za \u00fa\u010delem:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>prevenci overtreatmentu (nap\u0159. u pacient\u016f s MSI-H nebo POLE mutacemi),<\/li>\n\n\n\n<li>tak eskalace terapie (nap\u0159. vyu\u017eit\u00ed aspirinu u pacient\u016f s mutacemi PIK3CA).<\/li>\n<\/ul>\n\n\n\n<p>Nejnov\u011bj\u0161\u00ed pokyny NCCN (\u010dervenec 2025): <a href=\"https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/NCCN_Guidelines.pdf\">https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/NCCN_Guidelines.pdf<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nep\u0159etr\u017eit\u00fd v\u00fdvoj v oblasti molekul\u00e1rn\u00ed onkologie z\u00e1sadn\u00edm zp\u016fsobem m\u011bn\u00ed terapeutick\u00fd p\u0159\u00edstup k l\u00e9\u010db\u011b kolorekt\u00e1ln\u00edho karcinomu. V\u00fdsledky studie ALASCCA, prezentovan\u00e9 na kongresu ASCO GI 2025, spolu s aktualizovan\u00fdmi doporu\u010den\u00edmi NCCN pro [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":16450,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[78],"tags":[],"class_list":["post-16243","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-cs"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.0 (Yoast SEO v24.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AKTUALIZOVAN\u00c9 DOPORU\u010cEN\u00c9 POSTUPY NCCN PRO \u010cASN\u00c1 STADIA KOLOREKT\u00c1LN\u00cdHO KARCINOMU: V\u00ddZNAM BIOMARKER\u016e PIK3CA, POLE A MSI V \u0158\u00cdZEN\u00cd ADJUVANTN\u00cd L\u00c9\u010cBY - Genekor<\/title>\n<meta name=\"description\" content=\"Nov\u00e1 doporu\u010den\u00ed NCCN 2025 zahrnuj\u00ed PIK3CA, POLE a MSI jako biomarkery pro veden\u00ed adjuvantn\u00ed l\u00e9\u010dby u \u010dasn\u00e9ho kolorekt\u00e1ln\u00edho karcinomu.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/\" \/>\n<meta property=\"og:locale\" content=\"cs_CZ\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AKTUALIZOVAN\u00c9 DOPORU\u010cEN\u00c9 POSTUPY NCCN PRO \u010cASN\u00c1 STADIA KOLOREKT\u00c1LN\u00cdHO KARCINOMU: V\u00ddZNAM BIOMARKER\u016e PIK3CA, POLE A MSI V \u0158\u00cdZEN\u00cd ADJUVANTN\u00cd L\u00c9\u010cBY\" \/>\n<meta property=\"og:description\" content=\"Nov\u00e1 doporu\u010den\u00ed NCCN 2025 zahrnuj\u00ed PIK3CA, POLE a MSI jako biomarkery pro veden\u00ed adjuvantn\u00ed l\u00e9\u010dby u \u010dasn\u00e9ho kolorekt\u00e1ln\u00edho karcinomu.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/\" \/>\n<meta property=\"og:site_name\" content=\"Genekor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/genekorbiotechnology\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T13:30:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-07T06:48:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/f1c8313f-2a68-371b-9b88-90d6e6e6f965.png\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"394\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Ioanna Potska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napsal(a)\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ioanna Potska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Odhadovan\u00e1 doba \u010dten\u00ed\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuty\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/\"},\"author\":{\"name\":\"Ioanna Potska\",\"@id\":\"https:\/\/genekor.com\/cs\/#\/schema\/person\/d6c43cd4b4be66582d408967392cbcbd\"},\"headline\":\"AKTUALIZOVAN\u00c9 DOPORU\u010cEN\u00c9 POSTUPY NCCN PRO \u010cASN\u00c1 STADIA KOLOREKT\u00c1LN\u00cdHO KARCINOMU: V\u00ddZNAM BIOMARKER\u016e PIK3CA, POLE A MSI V \u0158\u00cdZEN\u00cd ADJUVANTN\u00cd L\u00c9\u010cBY\",\"datePublished\":\"2025-07-15T13:30:18+00:00\",\"dateModified\":\"2025-08-07T06:48:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/\"},\"wordCount\":462,\"publisher\":{\"@id\":\"https:\/\/genekor.com\/cs\/#organization\"},\"image\":{\"@id\":\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/f1c8313f-2a68-371b-9b88-90d6e6e6f965.png\",\"articleSection\":[\"Uncategorized @cs\"],\"inLanguage\":\"cs\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/\",\"url\":\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/\",\"name\":\"AKTUALIZOVAN\u00c9 DOPORU\u010cEN\u00c9 POSTUPY NCCN PRO \u010cASN\u00c1 STADIA KOLOREKT\u00c1LN\u00cdHO KARCINOMU: V\u00ddZNAM BIOMARKER\u016e PIK3CA, POLE A MSI V \u0158\u00cdZEN\u00cd ADJUVANTN\u00cd L\u00c9\u010cBY - Genekor\",\"isPartOf\":{\"@id\":\"https:\/\/genekor.com\/cs\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/f1c8313f-2a68-371b-9b88-90d6e6e6f965.png\",\"datePublished\":\"2025-07-15T13:30:18+00:00\",\"dateModified\":\"2025-08-07T06:48:42+00:00\",\"description\":\"Nov\u00e1 doporu\u010den\u00ed NCCN 2025 zahrnuj\u00ed PIK3CA, POLE a MSI jako biomarkery pro veden\u00ed adjuvantn\u00ed l\u00e9\u010dby u \u010dasn\u00e9ho kolorekt\u00e1ln\u00edho karcinomu.\",\"breadcrumb\":{\"@id\":\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#breadcrumb\"},\"inLanguage\":\"cs\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"cs\",\"@id\":\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#primaryimage\",\"url\":\"https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/f1c8313f-2a68-371b-9b88-90d6e6e6f965.png\",\"contentUrl\":\"https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/f1c8313f-2a68-371b-9b88-90d6e6e6f965.png\",\"width\":700,\"height\":394},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/genekor.com\/cs\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AKTUALIZOVAN\u00c9 DOPORU\u010cEN\u00c9 POSTUPY NCCN PRO \u010cASN\u00c1 STADIA KOLOREKT\u00c1LN\u00cdHO KARCINOMU: V\u00ddZNAM BIOMARKER\u016e PIK3CA, POLE A MSI V \u0158\u00cdZEN\u00cd ADJUVANTN\u00cd L\u00c9\u010cBY\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/genekor.com\/cs\/#website\",\"url\":\"https:\/\/genekor.com\/cs\/\",\"name\":\"Genekor\",\"description\":\"\u039c\u03bf\u03c1\u03b9\u03b1\u03ba\u03ae \u0393\u03b5\u03bd\u03b5\u03c4\u03b9\u03ba\u03ae\",\"publisher\":{\"@id\":\"https:\/\/genekor.com\/cs\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/genekor.com\/cs\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"cs\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/genekor.com\/cs\/#organization\",\"name\":\"Genekor\",\"url\":\"https:\/\/genekor.com\/cs\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"cs\",\"@id\":\"https:\/\/genekor.com\/cs\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/genekor.com\/wp-content\/uploads\/2021\/09\/logo-black.svg\",\"contentUrl\":\"https:\/\/genekor.com\/wp-content\/uploads\/2021\/09\/logo-black.svg\",\"width\":1,\"height\":1,\"caption\":\"Genekor\"},\"image\":{\"@id\":\"https:\/\/genekor.com\/cs\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/genekorbiotechnology\/\",\"https:\/\/gr.linkedin.com\/company\/genekor-sa\",\"https:\/\/www.youtube.com\/channel\/UCKC7sMFecVBY-OZAlRBHNzA\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/genekor.com\/cs\/#\/schema\/person\/d6c43cd4b4be66582d408967392cbcbd\",\"name\":\"Ioanna Potska\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"cs\",\"@id\":\"https:\/\/genekor.com\/cs\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ef44ac80c13d1335f0ea78257146bbf1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ef44ac80c13d1335f0ea78257146bbf1?s=96&d=mm&r=g\",\"caption\":\"Ioanna Potska\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AKTUALIZOVAN\u00c9 DOPORU\u010cEN\u00c9 POSTUPY NCCN PRO \u010cASN\u00c1 STADIA KOLOREKT\u00c1LN\u00cdHO KARCINOMU: V\u00ddZNAM BIOMARKER\u016e PIK3CA, POLE A MSI V \u0158\u00cdZEN\u00cd ADJUVANTN\u00cd L\u00c9\u010cBY - Genekor","description":"Nov\u00e1 doporu\u010den\u00ed NCCN 2025 zahrnuj\u00ed PIK3CA, POLE a MSI jako biomarkery pro veden\u00ed adjuvantn\u00ed l\u00e9\u010dby u \u010dasn\u00e9ho kolorekt\u00e1ln\u00edho karcinomu.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/","og_locale":"cs_CZ","og_type":"article","og_title":"AKTUALIZOVAN\u00c9 DOPORU\u010cEN\u00c9 POSTUPY NCCN PRO \u010cASN\u00c1 STADIA KOLOREKT\u00c1LN\u00cdHO KARCINOMU: V\u00ddZNAM BIOMARKER\u016e PIK3CA, POLE A MSI V \u0158\u00cdZEN\u00cd ADJUVANTN\u00cd L\u00c9\u010cBY","og_description":"Nov\u00e1 doporu\u010den\u00ed NCCN 2025 zahrnuj\u00ed PIK3CA, POLE a MSI jako biomarkery pro veden\u00ed adjuvantn\u00ed l\u00e9\u010dby u \u010dasn\u00e9ho kolorekt\u00e1ln\u00edho karcinomu.","og_url":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/","og_site_name":"Genekor","article_publisher":"https:\/\/www.facebook.com\/genekorbiotechnology\/","article_published_time":"2025-07-15T13:30:18+00:00","article_modified_time":"2025-08-07T06:48:42+00:00","og_image":[{"width":700,"height":394,"url":"https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/f1c8313f-2a68-371b-9b88-90d6e6e6f965.png","type":"image\/png"}],"author":"Ioanna Potska","twitter_card":"summary_large_image","twitter_misc":{"Napsal(a)":"Ioanna Potska","Odhadovan\u00e1 doba \u010dten\u00ed":"2 minuty"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#article","isPartOf":{"@id":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/"},"author":{"name":"Ioanna Potska","@id":"https:\/\/genekor.com\/cs\/#\/schema\/person\/d6c43cd4b4be66582d408967392cbcbd"},"headline":"AKTUALIZOVAN\u00c9 DOPORU\u010cEN\u00c9 POSTUPY NCCN PRO \u010cASN\u00c1 STADIA KOLOREKT\u00c1LN\u00cdHO KARCINOMU: V\u00ddZNAM BIOMARKER\u016e PIK3CA, POLE A MSI V \u0158\u00cdZEN\u00cd ADJUVANTN\u00cd L\u00c9\u010cBY","datePublished":"2025-07-15T13:30:18+00:00","dateModified":"2025-08-07T06:48:42+00:00","mainEntityOfPage":{"@id":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/"},"wordCount":462,"publisher":{"@id":"https:\/\/genekor.com\/cs\/#organization"},"image":{"@id":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#primaryimage"},"thumbnailUrl":"https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/f1c8313f-2a68-371b-9b88-90d6e6e6f965.png","articleSection":["Uncategorized @cs"],"inLanguage":"cs"},{"@type":"WebPage","@id":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/","url":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/","name":"AKTUALIZOVAN\u00c9 DOPORU\u010cEN\u00c9 POSTUPY NCCN PRO \u010cASN\u00c1 STADIA KOLOREKT\u00c1LN\u00cdHO KARCINOMU: V\u00ddZNAM BIOMARKER\u016e PIK3CA, POLE A MSI V \u0158\u00cdZEN\u00cd ADJUVANTN\u00cd L\u00c9\u010cBY - Genekor","isPartOf":{"@id":"https:\/\/genekor.com\/cs\/#website"},"primaryImageOfPage":{"@id":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#primaryimage"},"image":{"@id":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#primaryimage"},"thumbnailUrl":"https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/f1c8313f-2a68-371b-9b88-90d6e6e6f965.png","datePublished":"2025-07-15T13:30:18+00:00","dateModified":"2025-08-07T06:48:42+00:00","description":"Nov\u00e1 doporu\u010den\u00ed NCCN 2025 zahrnuj\u00ed PIK3CA, POLE a MSI jako biomarkery pro veden\u00ed adjuvantn\u00ed l\u00e9\u010dby u \u010dasn\u00e9ho kolorekt\u00e1ln\u00edho karcinomu.","breadcrumb":{"@id":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#breadcrumb"},"inLanguage":"cs","potentialAction":[{"@type":"ReadAction","target":["https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/"]}]},{"@type":"ImageObject","inLanguage":"cs","@id":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#primaryimage","url":"https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/f1c8313f-2a68-371b-9b88-90d6e6e6f965.png","contentUrl":"https:\/\/genekor.com\/wp-content\/uploads\/2025\/07\/f1c8313f-2a68-371b-9b88-90d6e6e6f965.png","width":700,"height":394},{"@type":"BreadcrumbList","@id":"https:\/\/genekor.com\/cs\/2025\/07\/15\/pik3ca-adjuvantni-lecba-kolorektalni-karcinom\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/genekor.com\/cs\/"},{"@type":"ListItem","position":2,"name":"AKTUALIZOVAN\u00c9 DOPORU\u010cEN\u00c9 POSTUPY NCCN PRO \u010cASN\u00c1 STADIA KOLOREKT\u00c1LN\u00cdHO KARCINOMU: V\u00ddZNAM BIOMARKER\u016e PIK3CA, POLE A MSI V \u0158\u00cdZEN\u00cd ADJUVANTN\u00cd L\u00c9\u010cBY"}]},{"@type":"WebSite","@id":"https:\/\/genekor.com\/cs\/#website","url":"https:\/\/genekor.com\/cs\/","name":"Genekor","description":"\u039c\u03bf\u03c1\u03b9\u03b1\u03ba\u03ae \u0393\u03b5\u03bd\u03b5\u03c4\u03b9\u03ba\u03ae","publisher":{"@id":"https:\/\/genekor.com\/cs\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/genekor.com\/cs\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"cs"},{"@type":"Organization","@id":"https:\/\/genekor.com\/cs\/#organization","name":"Genekor","url":"https:\/\/genekor.com\/cs\/","logo":{"@type":"ImageObject","inLanguage":"cs","@id":"https:\/\/genekor.com\/cs\/#\/schema\/logo\/image\/","url":"https:\/\/genekor.com\/wp-content\/uploads\/2021\/09\/logo-black.svg","contentUrl":"https:\/\/genekor.com\/wp-content\/uploads\/2021\/09\/logo-black.svg","width":1,"height":1,"caption":"Genekor"},"image":{"@id":"https:\/\/genekor.com\/cs\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/genekorbiotechnology\/","https:\/\/gr.linkedin.com\/company\/genekor-sa","https:\/\/www.youtube.com\/channel\/UCKC7sMFecVBY-OZAlRBHNzA"]},{"@type":"Person","@id":"https:\/\/genekor.com\/cs\/#\/schema\/person\/d6c43cd4b4be66582d408967392cbcbd","name":"Ioanna Potska","image":{"@type":"ImageObject","inLanguage":"cs","@id":"https:\/\/genekor.com\/cs\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ef44ac80c13d1335f0ea78257146bbf1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ef44ac80c13d1335f0ea78257146bbf1?s=96&d=mm&r=g","caption":"Ioanna Potska"}}]}},"_links":{"self":[{"href":"https:\/\/genekor.com\/cs\/wp-json\/wp\/v2\/posts\/16243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genekor.com\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/genekor.com\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/genekor.com\/cs\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/genekor.com\/cs\/wp-json\/wp\/v2\/comments?post=16243"}],"version-history":[{"count":8,"href":"https:\/\/genekor.com\/cs\/wp-json\/wp\/v2\/posts\/16243\/revisions"}],"predecessor-version":[{"id":16623,"href":"https:\/\/genekor.com\/cs\/wp-json\/wp\/v2\/posts\/16243\/revisions\/16623"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genekor.com\/cs\/wp-json\/wp\/v2\/media\/16450"}],"wp:attachment":[{"href":"https:\/\/genekor.com\/cs\/wp-json\/wp\/v2\/media?parent=16243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/genekor.com\/cs\/wp-json\/wp\/v2\/categories?post=16243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/genekor.com\/cs\/wp-json\/wp\/v2\/tags?post=16243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}